Susan E Kane
Overview
Explore the profile of Susan E Kane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lenz G, Hamilton A, Geng S, Hong T, Kalkum M, Momand J, et al.
Clin Cancer Res
. 2017 Nov;
24(5):1216-1226.
PMID: 29180608
Increased glycolysis and glucose dependence is a hallmark of malignancy that enables tumors to maximize cell proliferation. In HER2 cancers, an increase in glycolytic capacity is associated with trastuzumab resistance....
2.
Momand J, Magdziarz P, Feng Y, Jiang D, Parga E, Celis A, et al.
FEBS Open Bio
. 2017 Sep;
7(9):1328-1337.
PMID: 28904862
t-Darpp (truncated isoform of dopamine- and cAMP-regulated phosphoprotein) is a protein encoded by the gene and is expressed in breast, colon, esophageal, gastric, and prostate cancers, as well as in...
3.
Theile D, Geng S, Denny E, Momand J, Kane S
Cell Signal
. 2017 Sep;
40:53-61.
PMID: 28867659
t-Darpp is the truncated form of the dopamine- and cAMP-regulated phosphoprotein of 32kDa (Darpp-32) and has been demonstrated to confer resistance to trastuzumab, a Her2-targeted anticancer agent, via sustained signaling...
4.
Sadava D, Kane S
Biochem Biophys Res Commun
. 2017 Aug;
493(1):783-787.
PMID: 28847728
Small-cell lung carcinoma (SCLC) has a dismal prognosis in part because of multidrug resistance (MDR). Epibrassinolide (EB) is a steroid hormone in plants, with many physiological effects. It acts via...
5.
Christenson J, Denny E, Kane S
Oncotarget
. 2015 Oct;
6(32):33134-45.
PMID: 26430732
Drug resistance is a major barrier to successful cancer treatment. For patients with HER2-positive breast cancer who initially respond to therapy, the majority develop resistance within one year of treatment....
6.
Denny E, Kane S
PLoS One
. 2015 Jun;
10(6):e0132267.
PMID: 26121470
Trastuzumab has led to improved survival rates of HER2+ breast cancer patients. However, acquired resistance remains a problem in the majority of cases. t-Darpp is over-expressed in trastuzumab-resistant cell lines...
7.
Kane S, Holler L, Braun L, Neill J, Young D, Ridpath J, et al.
J Am Vet Med Assoc
. 2015 Jun;
246(12):1358-62.
PMID: 26043135
Case Description: 136 pregnant beef cows were purchased in the fall of 2003. The following spring, 128 cows calved as expected; 8 cows were believed to have aborted with the...
8.
Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al.
Mol Cancer Ther
. 2015 Apr;
14(6):1376-84.
PMID: 25840583
Brentuximab vedotin (BV) is an antibody-drug conjugate that specifically delivers the potent cytotoxic drug monomethyl auristatin E (MMAE) to CD30-positive cells. BV is FDA approved for treatment of relapsed/refractory Hodgkin...
9.
Christenson J, Kane S
Mol Cancer
. 2014 Aug;
13:192.
PMID: 25128420
Background: Darpp-32 and t-Darpp are expressed in several forms of breast cancer. Both are transcribed from the gene PPP1R1B via alternative promoters. In humans, Darpp-32 is expressed in both normal...
10.
Wang L, Xie Y, Ahmed K, Ahmed S, Sami A, Chibbar R, et al.
Breast Cancer Res Treat
. 2013 Jul;
140(2):273-84.
PMID: 23881522
One of the major obstacles in human epidermal growth factor receptor 2 (HER2)-specific trastuzumab antibody immunotherapy of HER2-positive breast cancer is the development of trastuzumab resistance, warranting the search for...